Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.

This study has been completed.
Information provided by (Responsible Party):
Omeros Corporation Identifier:
First received: July 22, 2008
Last updated: July 16, 2014
Last verified: July 2014
This is an exploratory study to determine the safety and clinical benefit of OMS302 Injection in subjects undergoing Cataract Extraction with Lens Replacement (CELR) using a coaxial phacoemulsification process.

Condition Intervention Phase
Cataract Extraction
Drug: OMS302
Drug: OMS302-PE
Drug: Vehicle
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Controlled, Double-Masked, Multicenter, Exploratory Study of the Clinical Benefit and Safety of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR) Using a Coaxial Phacoemulsification Process

Resource links provided by NLM:

Further study details as provided by Omeros Corporation:

Primary Outcome Measures:
  • Pupil diameter [ Time Frame: Day of Surgery ]
  • Pain and other measures of ocular discomfort [ Time Frame: 14 days ]
  • Degree of inflammation in the anterior chamber [ Time Frame: 14 days ]

Secondary Outcome Measures:
  • Ocular safety and changes in visual activity and intraocular pressure [ Time Frame: 28 days ]
  • General measures of safety [ Time Frame: 28 days ]

Enrollment: 60
Study Start Date: May 2008
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
OMS302 Irrigation Solution
Drug: OMS302
OMS302 Irrigation Solution
Other Name: OMS302 Irrigation Solution
Active Comparator: 2
OMS302-PE HCl Irrigation Solution
Drug: OMS302-PE
OMS302-PE HCI Irrigation Solution
Other Name: OMS302-PE HCI Irrigation Solution
Placebo Comparator: 3
Standard topical mydriatics and BSS Irrigation Solution
Drug: Vehicle
Standard topical mydriatics and Balanced Salt Solution Irrigation Solution
Other Name: Standard topical mydriatics and Balanced Salt Solution Irrigation Solution

Detailed Description:
OMS302 Injection is a mydriatic/anti-inflammatory combination investigational drug product being developed as an irrigation solution during intracameral lens replacement surgical procedures of the eye. OMS302 irrigation solution may induce and maintain an adequately dilated pupil and reduce postoperative symptoms of discomfort such as eye pain and irritation. The use of OMS302 irrigation solution may eliminate the need for pre-operative dilation of the eye and could reduce the postoperative use of an anti-inflammatory and pain medications following surgery.

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject is 50 years of age or older.
  • Subject is to undergo unilateral primary CELR for an age-related cataract under topical anesthesia and using a clear cornea incision.
  • Subject's history and physical examination are within normal limits or the examination is clinically non-significant for purposes of the study as determined by the Investigator, and subject is in good general health.
  • Subject has best corrected visual acuity (BCVA) of 20/400 or better in the non-study eye.
  • Subject has intraocular pressure (IOP) between 5 mmHg and 22 mmHg, inclusive, in the study eye.

Exclusion Criteria:

  • Subject is allergic to any of the individual ingredients in OMS302
  • Subject who is taking medications with the same activities as that of the active ingredients in OMS302 for defined time intervals prior to and after surgery.
  • Female subject of childbearing potential (i.e., not surgically sterilized nor post-menopausal longer than one year) who is not using an effective method of birth control within at least 14 days prior to surgery or has a positive pregnancy test.
  • Subject who has a present condition or history of any clinically significant uncontrolled gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, connective tissue, respiratory, or medical disorder as determined by the Investigator.
  • Subject who is taking anticoagulants.
  • Subject who is taking or needs to take for the duration of the study any of the prohibited medications.
  • Subject with pseudo-capsular exfoliation, or evidence of prior iritis or of ocular trauma with iris damage, or who has used pilocarpine within six months of screening.
  • Subject that has uncontrolled chronic ocular disease.
  • Subject that has active corneal pathology or scarring noted in either eye (except superficial punctate keratopathy in the non-study eye).
  • Subject that has extraocular/intraocular inflammation in either eye.
  • Subject has an active bacterial and/or viral infection in either eye.
  • Subject that has narrow-angle glaucoma, unstable glaucoma, or glaucoma being treated with prostaglandins or prostaglandin analogues.
  • Subject taking, or has taken within the past year, an alpha adrenergic antagonist.
  • Subject that has participated in or is currently participating in any investigational drug or device trial within the previous 30 days prior to the day of surgery.
  • Subject that has had intraocular conventional surgery within the past three months or intraocular laser surgery within one month of the planned surgery in the study eye.
  • Subject that requires the use of other topical medications during the trial except prophylactic antibiotics, topical lid care or glaucoma medications or tear replacement solutions.
  • Subject that needs other ocular surgery at the time of the cataract extraction.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00721695

United States, California
Shasta Eye Medical Group
Redding, California, United States, 96002
United States, Minnesota
Chu Vision Institute
Bloomington, Minnesota, United States, 55420
United States, Missouri
Silverstein Eye Centers
Kansas City, Missouri, United States, 64133
United States, Wisconsin
Davis Duehr Dean
Madison, Wisconsin, United States, 53715
Sponsors and Collaborators
Omeros Corporation
Study Director: Scott Houston Omeros Corporation
  More Information

Responsible Party: Omeros Corporation Identifier: NCT00721695     History of Changes
Other Study ID Numbers: C07-005
Study First Received: July 22, 2008
Last Updated: July 16, 2014

Keywords provided by Omeros Corporation:
Cataract Extraction
Lens Implantation

Additional relevant MeSH terms:
Lens Diseases
Eye Diseases
Pharmaceutical Solutions
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs processed this record on April 27, 2017